Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged (NOVO) Stock Price & Analysis

112 Followers

NOVO Stock Chart & Stats

CA$18.05CA$0.28(1.58%)

At close: Nov 11 4:00 PM EST

Day’s Range: CAD 17.65 - CAD 18.10
52-Week Range: CAD 14.88 - CAD 27.58
Previous Close: CAD 17.77
Volume: N/A
Average Volume (3M): 12.85K
Market Cap: CAD 254.57B
Enterprise Value: N/A
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): 10.7
Beta: 0.72
Next Earnings: Feb 03, 2027 (Est.)
EPS Estimate: N/A
Last Dividend Ex-Date: Aug 17, 2026
Dividend Yield: 3.44%

Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged News

Novo Nordisk announces new real-world data from PLATINUM-Truveta, RHODIUM-2

Novo Nordisk (NVO) announced new real-world data from PLATINUM-Truveta and RHODIUM-2, which are two retrospective studies evaluating associations between semaglutide 2.4 mg once-weekly injection use versus those not initiating treatment

5d agoNVO NOV

Novo Nordisk price target raised to DKK 298 from DKK 296 at Citi

Citi raised the firm’s price target on Novo Nordisk (NVO) to DKK 298 from DKK 296 and keeps a Neutral rating on the shares. Published first on TheFly – the

6d agoNVO NOV

Morning Movers: Datadog declines following third quarter earnings

Stock futures are sharply higher as investors react to the Democrats’ sweep of the midterm elections, with the party winning control of both the House and Senate. The election results

1w agoAMD CAR

Moderately bullish activity in Novo Nordisk with shares down 0.31%

Moderately bullish activity in Novo Nordisk (NVO), with shares down 12c near $40.33. Options volume roughly in line with average with 32k contracts traded and calls leading puts for a

1w agoNVO NOV

Cboe data suggests bullish flow in Novo Nordisk with shares up 1.49%

Cboe data suggests bullish flow in Novo Nordisk (NVO), with shares up 58c, or 1.49%, near $39.73. Options volume more than double the daily average with 49k contracts traded and

1w agoNVO NOV

AbbVie Science Chief says interested in building out obesity assets

AbbVie (ABBV) Chief Scientific Officer Roopal Thakkar said on the company’s earnings call: “Yes, we continue to have interest to build out obesity assets. We are open to anything that

1w agoLLY NVO

Moderately bullish activity in Novo Nordisk with shares up 1.27%

Moderately bullish activity in Novo Nordisk (NVO), with shares up 48c, or 1.27%, near $38.77. Options volume roughly in line with average with 18k contracts traded and calls leading puts

2w agoNVO NOV

Moderately bullish activity in Novo Nordisk with shares up 0.24%

Moderately bullish activity in Novo Nordisk (NVO), with shares up 10c, or 0.24%, near $39.15. Options volume relatively light with 26k contracts traded and calls leading puts for a put/call

2w agoNVO NOV

FDA approves Novo Nordisk’s Awiqli for type 2 diabetes in kids 10 and older

The U.S. Food and Drug Administration has approved Awiqli injection, a long-acting insulin analog, as an adjunct to diet and exercise to improve glycemic control in pediatric patients aged 10

2w agoNVO NOV

Big Pharma’s Obesity Shopping Spree Is Moving Beyond GLP-1s. Palatin May Fit the Pattern (NASDAQ: PTN)

WSW, NY, October 21st, 2026, FinanceWire Recent acquisitions and licensing deals reveal what drugmakers want next: different biology, better dosing and treatments that can complement existing medicines. Palatin is developing

3w agoNVO PTN

Cboe data shows mixed options sentiment in Novo Nordisk with shares down 0.76%

Cboe data shows mixed options sentiment in Novo Nordisk (NVO), with shares down 30c near $38.53. Options volume roughly in line with average with 65k contracts traded and puts leading

3w agoNVO NOV

Novo Nordisk: Market Perform and $47 Price Target Maintained Amid Obesity Strength and Competitive Risks

Novo Nordisk, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Evan Seigerman from BMO Capital maintained a Hold rating on the stock and has a

1M agoNVO NOV

Novo Nordisk Kept at Hold as Analyst Maintains $47 Price Target Amid Strategic Uncertainty

BMO Capital analyst Evan Seigerman maintained a Hold rating on Novo Nordisk yesterday and set a price target of $47.00. Evan Seigerman has given his Hold rating due to a

1M agoNVO NOV

Entera is on the Cusp of the Trial That Could Unlock America’s Osteoporosis Drug Market (NASDAQ: ENTX)

WSW, NY, August 31st, 2026, FinanceWire The drugs that rebuild bone are locked inside a channel most patients never reach. Entera (NASDAQ:ENTX) is nearing the pivotal trial built to change

2M agoLLY NVO

NOVO FAQ

What was Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged’s price range in the past 12 months?

Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged lowest stock price was C$14.88 and its highest was C$27.58 in the past 12 months.

What is Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged’s market cap?

Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged’s market cap is C$254.57B.

When is Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Is Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged pay dividends?

Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged pays a dividend of C$0.244 which represents an annual dividend yield of 3.44%. See more information on Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged dividends here

What is Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged’s EPS estimate?

Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged have?

Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged has 3,390,128,000 shares outstanding.

Which hedge fund is a major shareholder of Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged?

Currently, no hedge funds are holding shares in TSE:NOVO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged (NOVO) Earnings & Revenues

Historic Earnings Reports

NOVO Earnings Call

Q3 2026

Earnings Call SentimentPositive

The call was broadly positive, with strong Q3 financial performance, improving patient volumes, substantial Wegovy and Ozempic pill momentum, meaningful pipeline progress, and multiple upcoming launches. These positives were tempered by broad 2026 growth guidance, U.S. sales declines, pricing and payer pressure, loss-of-exclusivity impacts, China headwinds, and normalization in U.K. Wegovy pill uptake.

View all TSE:NOVO earnings summaries

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	12	4	6
Technical Analysis	4	4	2
Moving Averages	8	0	4

Technical Analysis >

Similar Stocks

Stocks similar to TSE:NOVO
Company	Price & Change	Follow
TSE:ROGRoche Holding Ltd CAD Hedged CIBC CDR
TSE:NVSNovartis AG CAD Hedged CIBC CDR
TSE:SNYSanofi SA Unsponsored CDR Hedged Reg S
TSE:PFEPfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S
TSE:MRKMerck & Co., Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S

Compare TSE:NOVO Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

NOVO Stock Chart & Stats

Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged News

Novo Nordisk announces new real-world data from PLATINUM-Truveta, RHODIUM-2

Novo Nordisk price target raised to DKK 298 from DKK 296 at Citi

Morning Movers: Datadog declines following third quarter earnings

Moderately bullish activity in Novo Nordisk with shares down 0.31%

Cboe data suggests bullish flow in Novo Nordisk with shares up 1.49%

AbbVie Science Chief says interested in building out obesity assets

Moderately bullish activity in Novo Nordisk with shares up 1.27%

Moderately bullish activity in Novo Nordisk with shares up 0.24%

FDA approves Novo Nordisk’s Awiqli for type 2 diabetes in kids 10 and older

Big Pharma’s Obesity Shopping Spree Is Moving Beyond GLP-1s. Palatin May Fit the Pattern (NASDAQ: PTN)

Cboe data shows mixed options sentiment in Novo Nordisk with shares down 0.76%

Novo Nordisk: Market Perform and $47 Price Target Maintained Amid Obesity Strength and Competitive Risks

Novo Nordisk Kept at Hold as Analyst Maintains $47 Price Target Amid Strategic Uncertainty

Entera is on the Cusp of the Trial That Could Unlock America’s Osteoporosis Drug Market (NASDAQ: ENTX)

NOVO FAQ

Company Description

Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged

Novo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged (NOVO) Earnings & Revenues

NOVO Earnings Call

Earnings Call Sentiment|Positive

Technical Analysis

Overall Consensus

Similar Stocks

Popular Stocks

Become an Expert with TipRanks Premium

Earnings Call SentimentPositive